Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENAZA-5S PILOT TRIAL
2022-501537-23-00Phase 2Completed
- Sponsor
- Leipzig University
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Leipzig University. Primary endpoint: Response rate (CR or CRi) after up to 6 cycles of therapy (best response). Started May 2023; status: completed.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-501537-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501537-23-00.